Hanmi Pharm. Co., Ltd.

Hanmi Science Co., Ltd.

Hanmi Holdings Co., Ltd.

Kwee Hyun Suh

Tae Woo Kim

Young Gil Ahn

Tae Hee Ha

In Hwan Bae

Seok Jong Kang

Eun Joo Kwak

Gwan Sun Lee

Chang Hee Park

Jae Yul Choi

Won Jeoung Kim

Young Hoon Kim

Eun Young Kim

Ji Sook Kim

Hee Sook Oh

Ho Seok Kim

Maeng Sup Kim

Ji Young Song

Eun Sook Kim

Mi Young Cha

Ji Young Jeon

Kwang Ok Lee

Ju Yeon Lee

Mi Ra Kim

Myoung Gi Jo

Sang Mi Han

Jung Beom Son

Young Jin Ham

Seung Hyun Jung

Seo Hee Kim

Cheol Kyung Kim

Jae Hyuk Jung

Jong Ouk Baek

Eun Young Byun

Sang Min Yun

Seung Ah Jun

Sangmin Yun

Hee Cheol Kim

Mi Young Ko

Bo Sung Kwon

Wook Jang

Young Ho Moon

Nam Du Kim

Moon Sub Lee

Gi Jeong Kim

Mi Ra Seong

Chang Hee Dongho-Villa 203 Park

Provided are a pyrimidine compound represented by Formula 1, a method of preparing the compound, and a pharmaceutical use of the compound for the prevention or treatment of cancer.

Pyrimidine compounds and pharmaceutical compositions for preventing or treating cancers including the same

The present invention relates to a crystalline form of a salt of 4-amino-N-(1-((3-chloro-2-fluorophenyl)amino)-6-methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide, and a pharmaceutical composition containing the same. The crystalline form of the salt of the compound can be easily used for preparing a pharmaceutical composition containing the same as an active ingredient.

Salts of 4-amino-N-(l-((3-chloro-2-fluorophenyl)amino)-6-methylisoquinolin-5-yl)thieno[3,2-D]pyrimidine-7-carboxamide, and crystalline forms thereof

The present invention relates to a compound, 4-amino-N-(1-((3-chloro-2-fluoro-4-hydroxyphenyl)amino)-6-methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide, and pharmaceutically acceptable salts thereof having inhibitory activity for protein kinases.

Thieno[3,2-d]pyrimidine derivative compound having inhibitory activity for protein kinase

Provided are a pyrimidine compound represented by Formula 1, a method of preparing the same, and a pharmaceutical use of the pyrimidine compound for the prevention or treatment of cancer.

Pyrimidine compound and pharmaceutical use thereof

The present invention relates to a novel method for preparing thienopyrimidine compound having an activity of selectively inhibiting tyrosine kinase, specifically the mutant epidermal growth factor receptor tyrosine kinase; and a novel intermediate used therein. According to the method of the present invention, the industrial mass-production of the compound of Formula 1, which is useful as a therapeutic agent for non-small cell lung cancer induced by the mutant epidermal growth factor receptor tyrosine kinase, can be implemented more conveniently and efficiently than the conventional technology.

Process for preparing thienopyrimidine compound and intermediates used therein

Provided are a thieno[3,2-d]pyrimidine derivative of formula (I) or a pharmaceutically acceptable salt thereof having inhibitory activity for protein kinase, and a pharmaceutical composition comprising same for prevention and treatment of abnormal cell growth diseases.

Thieno[3,2-D]pyrimidine derivatives having inhibitory activity for protein kinases

A method for preparing a thienopyrimidine compound of Formula 1, which is a selective inhibitor of tyrosine kinase activity, in particular, of mutant epidermal growth factor receptor tyrosine kinase. Intermediates used in the method are provided.

Method for preparing thienopyrimidine compound and intermediates used therein

The present invention provides a novel method for preparing a thienopyrimidine compound of Formula 1, which is a selective inhibitor of tyrosine kinase activity, in particular, of mutant epidermal growth factor receptor tyrosine kinase, and novel intermediates used in the method.

The present invention relates to a novel bicyclic derivative that has an inhibitory activity against sodium-glucose linked transporters (SGLTs) present in the intestines and kidneys, or a pharmaceutically acceptable salt, isomer, hydrate or solvate thereof, and a pharmaceutical composition including the same as an active ingredient, which effectively inhibit the SGLT activity, and thus can be used as a therapeutic agent to treat diseases caused by hyperglycemia, such as diabetes including insulin-dependent diabetes (type I diabetes mellitus) and non-insulin-dependent diabetes (type II diabetes mellitus), diabetic complications, and obesity.

Bicyclic derivatives and pharmaceutical composition including the same

The present invention relates to a novel fused pyrimidine derivative having an inhibitory activity for tyrosine kinases, and a pharmaceutical composition for preventing or treating cancers, tumors, inflammatory diseases, autoimmune diseases, or immunologically mediated diseases comprising same as an active ingredient.

Fused pyrimidine derivatives for inhibition of tyrosine kinase activity

A compound selected from the group consisting of an isoquinoline-5-carboxamide derivative of formula (I), a pharmaceutically acceptable salt, an isomer, a hydrate and a solvate thereof is effective for the prevention or treatment of diseases associated with abnormal cell growth, which are caused by abnormal activation of a protein kinases.

Isoquinoline-5-carboxamide derivative having inhibitory activity for protein kinase

Growing community of inventors

Suwon-si, South Korea

Kwee Hyun Suh